Human papillomavirus genotypes and factors associated with major cervical smear abnormalities in a sickle cell endemic area of Kisangani, Democratic Republic of the Congo. - 2026
Human papillomavirus genotypes and factors associated with major cervical smear abnormalities in a sickle cell endemic area of Kisangani, Democratic Republic of the Congo.
Human papillomavirus genotypes and factors associated with major cervical smear abnormalities in a sickle cell endemic area of Kisangani, Democratic Republic of the Congo.pdf
Humans; Female; Democratic Republic of the Congo/epidemiology; Genotype; Adult; Cross-Sectional Studies; Vaginal Smears; Risk Factors; Young Adult; Middle Aged; Papillomavirus Infections/epidemiology; Papillomavirus Infections/virology; Papillomavirus Infections/complications; Human Papillomavirus Viruses/genetics; Papillomaviridae/genetics; Anemia, Sickle Cell/epidemiology; Anemia, Sickle Cell/complications; Uterine Cervical Neoplasms/epidemiology; Uterine Cervical Neoplasms/virology; Anemia, Sickle Cell; Democratic Republic of the Congo; Human Papillomavirus Viruses; Papillomaviridae; Papillomavirus Infections; Uterine Cervical Neoplasms; Multidisciplinary
Abstract :
[en] [en] BACKGROUND: Cervical cancer due to high-risk human papillomavirus (HR-HPV) is the leading gynecological cancer in Sub-Saharan Africa and in the Democratic Republic of the Congo (DRC), where approximately one-quarter of people carries the sickle cell allele. This study aims to identify the HR-HPV genotypes and factors associated with major cervical abnormalities among women living in the sickle cell endemic area of Kisangani, DRC.
METHODS: This hospital-based cross-sectional study consisted to a face-to-face and semi-structured questionnaire for collecting data of the socio-demographic, clinical and sexual behaviors characteristics of participants. The sickle cell status was confirmed using liquid chromatography coupled with mass spectrometry. Cervical smears were collected using the ThinPrep® Pap-test solution (Hologic Inc, Marlborough, USA). The HR-HPV molecular analysis was performed using the Cobas® 6800 system (Roche Molecular Systems, Somerville, USA) for real time polymerase chain reaction (RT-PCR) and the Oxford Nanopore platform (Oxford Nanopore Technologies, Oxford, England) for the viral genome sequencing. Cytological analyses were performed using the ThinPrep 5000 processor (Hologic), and the results were reported according to the 2014 Bethesda System classification. The logistic regression model was used to estimate the adjusted Odd ratio (aOR) during the risk factor assessments.
RESULTS: Among 712 women enrolled, the prevalence of HR-HPV was 28.4% (95% CI: 25.1-31.7). HPV35, HPV52 and HPV31 were the most common genotypes; while the sequencing identified two new variants of HPV103 and HPV223. The following factors were associated with HR-HPV infection: (i) age between 25 and 34 years (aOR: 2.10, 95% CI:1.22-3.69); (ii) being unmarried (aOR: 1.54, 95% CI: 1.05-2.27) and (iii) HIV-positive status (aOR: 14.85, 95% CI: 2.36-288.25). No correlation was observed between hemoglobin AS (HbAS) status and HR-HPV infection or cytological abnormalities. However, women aged 45-54 years (aOR: 3.8, 95% CI: 1.34-11.65), those using intravaginal herbal (aOR: 3.59, 95% CI: 1.26-11.28) and those infected with HPV33 (aOR: 8.45, 95% CI: 1.68-34.05) were more likely to present major cervical abnormalities in our series.
CONCLUSION: Our study shows a high prevalence of cervical HR-HPV infection in Kisangani, DRC. HPV35, HPV52, and HPV31 are the three most common genotypes, while novel variants of HPV types 103 and 223 were identified. Our findings also highlight that advanced age, HPV33 infection and intravaginal herbal use are the main factors associated with major cervical abnormalities. Although HbAS has not been associated with HR-HPV infection or cervical lesions, further studies are needed to determine this association in women with sickle cell disease (HbSS).
Disciplines :
Genetics & genetic processes
Author, co-author :
Neema Ufoy Mungu, Yvette ; Université de Liège - ULiège > GIGA ; Department of Gynecology and Obstetrics, Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic of the Congo
Desreux, Joëlle ; Université de Liège - ULiège > Département des sciences cliniques
Bianchi, Elettra ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Junior, Burubu Lisi-Ankiene; Department of Gynecology and Obstetrics, Faculty of Medicine, University of Kikwit, Kikwit, Democratic Republic of the Congo
Djang'eing'a, Roland Marini; Laboratory of Analytical Pharmaceutical Chemistry, CIRM, Faculty of Medicine, University of Liège, Liege, Belgium ; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic of the Congo
Keith, Durkin; Department of Biomedical and Preclinical Sciences, Human Genetics, GIGA Research, Faculty of Medicine, University of Liege, Liege, Belgium
Maria, Artesi; Department of Biomedical and Preclinical Sciences, Human Genetics, GIGA Research, Faculty of Medicine, University of Liege, Liege, Belgium
Bosunga, Katenga; Department of Gynecology and Obstetrics, Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic of the Congo
Bours, Vincent ; Université de Liège - ULiège > GIGA > GIGA Cancer - Human Genetics
Language :
English
Title :
Human papillomavirus genotypes and factors associated with major cervical smear abnormalities in a sickle cell endemic area of Kisangani, Democratic Republic of the Congo.
Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, Azizi M, Bastan R. An update on human papilloma virus vaccines: history, types, protection, and efficacy. Frontiers in Immunology. 2021;12:805695. https://doi.org/10.3389/fimmu.2021.805695
Scott-Wittenborn N, Fakhry C. Epidemiology of HPV related malignancies. Semin Radiat Oncol. 2021;31(4):286–96. https://doi.org/10.1016/j.semradonc.2021.04.001 PMID: 34455984
Shu Z, Zhao W, Zhan X, Zeng J, Li J. Epidemiology and genotypes analysis of human papillomavirus infection in Huizhou, China. Front Public Health. 2024;12:1440480. https://doi.org/10.3389/fpubh.2024.1440480 PMID: 39185110
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clinicians. 2024;74(3):229–63. https://doi.org/10.3322/caac.21834
OMS RDC. Faire progresser la lutte contre le cancer du col utérin en République Démocratique du Congo. 2024. https://www.afro.who.int/fr/countries/democratic-republic-of-congo/news/faire-progresser-la-lutte-contre-le-cancer-du-col-de-luterus-en-republique-democratique-du-congo
Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D. Human papillomavirus and related diseases in Democratic Republic of the Congo. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre); 2023. Accessed 2023 October 1. https://hpvcentre.net/statistics/reports/COD.pdf?t=1741340279355
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, De Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta‐analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99. https://doi.org/10.1086/657321
Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health. 2021;8:552028. https://doi.org/10.3389/fpubh.2020.55202
Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, et al. Human Papillomavirus and Related Diseases in the World. 2023. https://hpvcentre.net/datastatistics.php
Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJF, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366(9490):991–8. https://doi.org/10.1016/S0140-6736(05)67069-9 PMID: 16168781
Ouh YT, Min KJ, Cho HW, Ki M, Oh JK, Shin SY, et al. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014–2016. J Gynecol Oncol. 2018;29(1):e14. https://doi.org/10.3802/jgo.2018.29.e14
Kim M, Park NJ-Y, Jeong JY, Park JY. Multiple Human Papilloma Virus (HPV) infections are associated with HSIL and persistent HPV infection status in Korean patients. Viruses. 2021;13(7):1342. https://doi.org/10.3390/v13071342 PMID: 34372548
Ouedraogo RA, Kande A, Nadembega WMC, Ouermi D, Zohoncon TM, Djigma FW, et al. Distribution of high- and low-risk human papillomavirus genotypes and their prophylactic vaccination coverage among West African women: systematic review. J Egypt Natl Canc Inst. 2023;35(1):39. https://doi.org/10.1186/s43046-023-00196-x PMID: 38060078
McBride AA. Human papillomaviruses: diversity, infection and host interactions. Nat Rev Microbiol. 2022;20(2):95–108. https://doi.org/10.1038/ s41579-021-00617-5 PMID: 34522050
zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50. https://doi.org/10.1038/ nrc798 PMID: 12044010
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 1st ed. Geneva: World Health Organization; 2020.
Molina MA, Steenbergen RDM, Pumpe A, Kenyon AN, Melchers WJG. HPV integration and cervical cancer: a failed evolutionary viral trait. Trends Mol Med. 2024;30(9):890–902. https://doi.org/10.1016/j.molmed.2024.05.009 PMID: 38853085
Simoens C, Arbyn M, Gilles C, Dewilde K. Clinical guidance: supporting the introduction of the HPV test in cervical cancer screening in Belgium. Bruxelles. 2024. https://www.sciensano.be/fr/screening-cancer-du-col-de-luterus
Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1:104. https://doi.org/10.1038/ncomms1104 PMID: 21045822
Tshilolo L, Aissi LM. Guide pratique de diagnostic précoce et de prise en charge de la drépanocytose en Afrique. Centre de Formation et d’Appui sanitaire/CEFA; 2009.
Burubu JLA, Juakali JJS, Otuli NL, Bosenge JDN, Matega TH, Neema YUM, et al. Sickle cell trait in Kisangani: prevalence and opinion of carriers towards the choice of a potential carrier spouse. JBM. 2025;13(02):202–17. https://doi.org/10.4236/jbm.2025.132016
Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA. 2014;312(20):2115–25. https://doi.org/10.1001/jama.2014.15063 PMID: 25393378
Ataga KI, Saraf SL, Derebail VK. The nephropathy of sickle cell trait and sickle cell disease. Nat Rev Nephrol. 2022;18(6):361–77. https://doi.org/10.1038/s41581-022-00540-9 PMID: 35190716
Allali M, El Fermi R, Errafii K, Abdelaziz W, Al Idrissi N, Fichtali K, et al. HPV genotypes in Africa: comprehensive analysis of genetic diversity and evolutionary dynamics. Arch Virol. 2025;170(6):116. https://doi.org/10.1007/s00705-025-06299-1 PMID: 40299107
Mutombo AB, Benoy I, Tozin R, Bogers J, Van Geertruyden JP, Jacquemyn Y. Prevalence and distribution of human papillomavirus genotypes among women in Kinshasa, the Democratic Republic of the Congo. JGO. 2019;5:1–9. https://doi.org/10.1200/JGO.19.00110
Muwonga Tukisadila J, Mboumba Bouassa RS, Tonen-Wolyec S, Loemba H, Muwonga J, Belec L. Syndemic synergy of HPV, HIV, and HSV-2 for oncogenic HPV replication in female sex workers. TropicalMed. 2025;10(6):157. https://doi.org/10.3390/tropicalmed10060157
Nyakio O, Kibukila F, Kasongo B, Chasinga T, Murenzi G, Tambwe A, et al. The place of human papillomavirus test in the screening of intraepithelial lesions of cervix in South-Kivu Province, DR Congo. OJOG. 2021;11(09):1125–32. https://doi.org/10.4236/ojog.2021.119106
Ali-Risasi C, Mulumba P, Verdonck K, Vanden Broeck D, Praet M. Knowledge, attitude and practice about cancer of the uterine cervix among women living in Kinshasa, the Democratic Republic of Congo. BMC Womens Health. 2014;14(1):30. https://doi.org/10.1186/1472-6874-14-30 PMID: 24548698
Stratégie nationale de lutte contre les cancers du col utérin et du sein en République Démocratique Du Congo. Kinshasa: Programme national de santé de la reproduction; 2015. https://www.iccp-portal.org/plans/ strategie-nationale-de-lutte-contre-les-cancers-du-col-uterin-et-du-sein-en-republique
Asempah E, Ikpebe E. Accelerating HPV vaccination in Africa for health equity. Glob Health Res Policy. 2024;9(1):37. https://doi.org/10.1186/ s41256-024-00380-z
CNRP. Trousses de détection des HPV ayant bénéficié d’une validation clinique pour le dépistage du cancer du col de l’utérus. 2024. Accessed 2025 December 10. https://cnr-hpv.fr/wp-content/uploads/2024/09
Belgium: University Hospital Center of Liege; 2025. https://www.chuliege.be/jcms/c2_18904107/laboratoire-unilab-lg/accreditation
RDC-Institut National de la Statistique, École de Santé Publique de Kinshasa, I C F. Enquête démographique et de santé de République Démocratique du Congo 2023–2024: rapport final. Rockville, Maryland, USA: ICF; 2025. https://drc.unfpa.org/sites/default/files/pub-pdf/2025-02/RDC%2C%20EDS%202023-2024.pdf
Nayar R, Wilbur DC. The Bethesda system for reporting cervical cytology: definitions, criteria, and explanatory notes. Third ed. Switzerland: Springer International Publishing; 2015.
Saville M, Sultana F, Malloy MJ, Velentzis LS, Caruana M, Ip ELO, et al. Clinical validation of the cobas HPV test on the cobas 6800 system for the purpose of cervical screening. J Clin Microbiol. 2019;57(2):e01239-18. https://doi.org/10.1128/JCM.01239-18 PMID: 30463896
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441. PMID: 23189750
Artesia M, Neema-UfoyMungu Y, Yassine El M, Palmeira L, Elettra B, Burubu JLA. Nanopore sequencing of high-risk HPV via amplicon and rolling circle amplification points to HPV integration and identifies new HPV types. bioRxiv. 2026. Forthcoming article
Steele C, Sinski A, Asibey J, Hardy-Dessources M-D, Elana G, Brennan C, et al. Point-of-care screening for sickle cell disease in low-resource settings: a multi-center evaluation of HemoTypeSC, a novel rapid test. Am J Hematol. 2019;94(1):39–45. https://doi.org/10.1002/ajh.25305 PMID: 30290004
Boemer F, Ketelslegers O, Minon J-M, Bours V, Schoos R. Newborn screening for sickle cell disease using tandem mass spectrometry. Clin Chem. 2008;54(12):2036–41. https://doi.org/10.1373/clinchem.2008.106369 PMID: 18832473
Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022;10(8):e1115–27. https://doi.org/10.1016/ S2214-109X(22)00241-8 PMID: 35839811
Moscicki A-B, Flowers L, Huchko MJ, Long ME, MacLaughlin KL, Murphy J, et al. Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 2019;23(2):87–101. https://doi.org/10.1097/LGT.0000000000000468 PMID: 30907775
Liu G, Sharma M, Tan N, Barnabas R. HIV-positive women have higher risk of HPV infection, precancerous lesions, and cervical cancer: a systematic review and meta-analysis. AIDS. 2018;32(6):795–808. https://doi.org/10.1097/QAD.0000000000001765
Paluku JL, Carter TE, Lee M, Bartels SA. Massive single visit cervical pre-cancer and cancer screening in eastern Democratic Republic of Congo. BMC Women’s Health. 2019;19:43. https://doi.org/10.1186/s12905-019-0737-y
Sangwa-Lugoma G, Ramanakumar AV, Mahmud S, Liaras J, Kayembe PK, Tozin RR, et al. Prevalence and determinants of high-risk human papillomavirus infection in women from a sub-Saharan African community. Sex Transm Dis. 2011;38(4):308–15. https://doi.org/10.1097/OLQ.0b013e-3181fc6ec0 PMID: 21150817
Murenzi G, Vuhahula E, Kimambo A, Matiku S, Tuyishime O, Liwa E, et al. High-risk human papillomavirus genotyping in cervical cancers in Tanzania. Infect Agent Cancer. 2024;19(1):35. https://doi.org/10.1186/s13027-024-00596-1 PMID: 39103953
Mchome BL, Kjaer SK, Manongi R, Swai P, Waldstroem M, Iftner T, et al. HPV types, cervical high-grade lesions and risk factors for oncogenic human papillomavirus infection among 3416 Tanzanian women. Sex Transm Infect. 2021;97(1):56–62. https://doi.org/10.1136/sextrans-2019-054263 PMID: 32269071
Okoye JO, Chukwukelu CF, Okekpa SI, Ogenyi SI, Onyekachi-Umah IN, Ngokere AA. Racial disparities associated with the prevalence of vaccine and non-vaccine HPV types and multiple HPV infections between Asia and Africa: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2021;22(9):2729–41. https://doi.org/10.31557/APJCP.2021.22.9.2729
Pinheiro M, Gage JC, Clifford GM, Demarco M, Cheung LC, Chen Z, et al. Association of HPV35 with cervical carcinogenesis among women of African ancestry: evidence of viral-host interaction with implications for disease intervention. Int J Cancer. 2020;147(10):2677–86. https://doi.org/10.1002/ijc.33033 PMID: 32363580
Linda M, Abel N, ALice N, Hellen L. Protecting Women and Girls in the Democratic Republic of Congo (DRC) Against Cervical Cancer. World Bank Group; 2025. Accessed 2023 October 1. https://www.banquemondiale.org/fr/news/feature/2025/08/19/ protecting-women-and-girls-in-the-democratic-republic-of-congo-drc-against-cervical-cancer
Arroyo Mühr LS, Gini A, Yilmaz E, Hassan SS, Lagheden C, Hultin E, et al. Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer. Nat Commun. 2024;15(1):3679. https://doi.org/10.1038/s41467-024-47909-x PMID: 38693149
Gray P, Wang J, Nordqvist Kleppe S, Elfström KM, Dillner J. Population-based age-period-cohort analysis of declining human papillomavirus prevalence. J Infect Dis. 2025;231(4):e638–49. https://doi.org/10.1093/infdis/jiaf032 PMID: 39841153
Guo W, Hu Z, Yan J, Shen X, Meng Q, Wu H, et al. Epidemiological study of human papillomavirus infection in 105,679 women in Wuhan, China. BMC Infect Dis. 2024;24(1):1111. https://doi.org/10.1186/s12879-024-10011-0 PMID: 39375610
de Villiers E-M. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1–2):2–10. https://doi.org/10.1016/j.virol.2013.04.023 PMID: 23683837
Dutta S, Robitaille A, Aubin F, Fouéré S, Galicier L, Boutboul D, et al. Identification and characterization of two novel Gammapapillomavirus genomes in skin of an immunosuppressed Epidermodysplasia Verruciformis patient. Virus Res. 2018;249:66–8. https://doi.org/10.1016/j.virusres.2018.03.003 PMID: 29526719
Chen Z, Schiffman M, Herrero R, Desalle R, Burk RD. Human papillomavirus (HPV) types 101 and 103 isolated from cervicovaginal cells lack an E6 open reading frame (ORF) and are related to gamma-papillomaviruses. Virology. 2007;360(2):447–53. https://doi.org/10.1016/j.virol.2006.10.022 PMID: 17125811
Chatterjee N, Sultana F, Roy R, Dey S, Naskar S, Dam A, et al. Prevalence of novel gamma HPV types 223 and 225 in oral cavity and skin of Indian normal and neoplastic participants. J Med Virol. 2023;95(8):e29019. https://doi.org/10.1002/jmv.29019 PMID: 37543989
de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13. https://doi.org/10.1016/j.bpobgyn.2017.08.015 PMID: 28964706
IARC working group. Monographs on the evaluation of carcinogenic risks to humans. France: WHO Press; 2007. https://publications.iarc.who.int/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Human-Papillomaviruses-2007
Luo Q, Zhang H, Zeng X, Han N, Ma Z, Luo H. HPV specificity and multiple infections and association with cervical cytology in Chongqing, China: a cross-sectional study. BMC Infect Dis. 2024;24(1):804. https://doi.org/10.1186/s12879-024-09693-3 PMID: 39123121
Mayaud P, Kelly H, Ngou J, Chikandiwa A, Sawadogo B, Omar T, et al. Incidence, persistance et clairance des génotypes HPV à haut-risque en relation avec le développement de lésions cervicales, et influence des paramètres immunologiques dans une cohorte des femmes africaines infectées par le VIH-1 (Étude HARP). Revue Francophone des Laboratoires. 2014;2014(465):7. https://doi.org/10.1016/s1773-035x(14)72658-9
Bruno MT, Valenti G, Cavallaro AG, Palermo I, Aiello T, Farina J, et al. Extended genotyping to stratify the risk of CIN2+ in women with persistent HPV Infection, negative cytology and Type 3 transformation zone. Cancers (Basel). 2024;16(10):1816. https://doi.org/10.3390/cancers16101816 PMID: 38791895
Asiri A, Bokahri BT, Sadaf, Eisa AA, Aljohani HM, Nofal W, et al. Curcumin, EGCG and apigenin in cervical cancer: mechanistic insights and therapeutic potential. Front Pharmacol. 2025;16:1592395. https://doi.org/10.3389/fphar.2025.1592395 PMID: 40667502
Poulios E, Papadopoulou SK, Psara E, Giaginis C. Antioxidant, antimicrobial, and anticancer activity of basil (Ocimum basilicum). Antioxidants (Basel). 2025;14(12):1469. https://doi.org/10.3390/antiox14121469 PMID: 41462669
Sinan KI, Ak G, Etienne OK, Jekő J, Cziáky Z, Gupcsó K, et al. Deeper insights on Alchornea cordifolia (Schumach. & Thonn.) Müll.Arg extracts: chemical profiles, biological abilities, network analysis and molecular docking. Biomolecules. 2021;11(2):219. https://doi.org/10.3390/ biom11020219
Delgado-Diaz DJ, Jesaveluk B, Hayward JA, Tyssen D, Alisoltani A, Potgieter M, et al. Lactic acid from vaginal microbiota enhances cervicovaginal epithelial barrier integrity by promoting tight junction protein expression. Microbiome. 2022;10(1):141. https://doi.org/10.1186/s40168-022-01337-5 PMID: 36045402
Norenhag J, Edfeldt G, Stålberg K, Garcia F, Hugerth LW, Engstrand L, et al. Compositional and functional differences of the vaginal microbiota of women with and without cervical dysplasia. Sci Rep. 2024;14(1):11183. https://doi.org/10.1038/s41598-024-61942-2 PMID: 38755259
Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215–22. https://doi.org/10.1128/CMR.05028-11 PMID: 22491770
Sourabié Y, Yonli YD, Fumoux F, Traoré Y. La réponse humorale contre les peptides antigéniques de Plasmodium falciparum (MSP1, MSP2 et SR-11.1) chez des sujets vivant en zone endémique. Pan Afr Med J. 2022;41. https://doi.org/10.11604/pamj.2022.41.250.30950
Al-Kateb H, Nguyen TT, Steger-May K, Pfeifer JD. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). Mol Oncol. 2015;9(9):1737–43. https://doi.org/10.1016/j.molonc.2015.05.004 PMID: 26071350
d’Avenia M, Dell’Anno F, Martinelli M, Santomauro L, Njoku RC, Arroyo Mühr LS, et al. Quality assurance in cervical cancer screening: evaluation of sample adequacy in HPV DNA testing. J Med Virol. 2025;97(7):e70482. https://doi.org/10.1002/jmv.70482 PMID: 40600419
Delahaye C, Nicolas J. Sequencing DNA with nanopores: troubles and biases. PLoS One. 2021;16(10):e0257521. https://doi.org/10.1371/journal.pone.0257521 PMID: 34597327